




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 215/26, A61K 31/47, C07D 215/22, 405/12		A1	(11) International Publication Number: WO 99/09011 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/JP98/03657		(81) Designated States: AU, BR, CA, CN, ID, KR, MX, SG, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 18 August 1998 (18.08.98)			
(30) Priority Data: 9/222431 19 August 1997 (19.08.97) JP		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kanda Tsukasacho 2-chome, Chiyoda-ku, Tokyo 101-8535 (JP).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): OSHIRO, Yasuo [JP/JP]; 61, Yoshinohoncho 6-chome, Tokushima-shi, Tokushima 770-0802 (JP). NISHI, Takao [JP/JP]; 2-28, Aza Tarohachisu Sotobiraki, Kitajimacho, Itano-gun, Tokushima 771-0202 (JP). KUWAHARA, Keiichi [JP/JP]; 1201-20, Shioya, Ako-shi, Hyogo 678-0201 (JP). WATANABE, Kozo [JP/JP]; 11-19, Tanakacho 1-chome, Higashinada-ku, Kobe-shi, Hyogo 658-0081 (JP).			
(74) Agents: ASAMURA, Kiyoshi et al.; New Otemachi Building, Room 331, 2-1, Otemachi 2-chome, Chiyoda-ku, Tokyo 100-0004 (JP).			

(54) Title: CARBOSTYRIL DERIVATIVES FOR INHIBITING SKIN ERYTHEMA AND/OR SKIN PIGMENTATION



(57) Abstract

The present invention provides an agent for inhibiting skin erythema and/or skin pigmentation, containing at least one selected from the group consisting of the carbostyryl derivative and salt thereof represented by general formula (1), wherein R¹ is a hydrogen atom, a lower alkyl group or the like; R² is a hydrogen atom, a lower alkyl group, a lower alkoxy group or the like; R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents or the like; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

DESCRIPTION


CARBOSTYRIL DERIVATIVES FOR INHIBITING SKIN ERYTHEMA AND/OR SKIN PIGMENTATION

TECHNICAL FIELD

The present invention relates to carbostyryl derivatives and agents for inhibiting skin erythema and/or skin pigmentation containing, as the effective ingredient, 5 said carbostyryl derivative.


BACKGROUND ART

JP-A-4-234386 discloses carbostyryl derivatives represented by the general formula (A),



10 (wherein R^A is a hydrogen atom or a lower alkyl group; R^B is a hydrogen atom, a lower alkyl group or a lower alkoxy group; and R^C is a lower alkyl group respectively) which can be used as intermediates for preparing other carbostyryl derivatives used for treating cardiovascular diseases.

15 Additionally, WO 93/22317 discloses carbostyryl derivatives represented by the general formula (B),



(wherein R^D and R^E are each the same or different from each other and are hydrogen atoms, lower alkyl groups or lower alkoxy groups; and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond) which can be used as intermediates for preparing quinoline derivatives used for remedy for cardiac diseases.

However, these prior art references disclose only that the above-mentioned carbostyryl derivatives can be used as intermediates for preparing blocking agents of adrenaline β -receptor or antiarrhythmic drugs. Thus, above-mentioned prior art references do not disclose at all that these carbostyryl derivatives per se possess whatever pharmacological activities.


Furthermore, WO 97/44037 and WO 97/44321 disclose quinoline compounds as antagonists of gonadotropin-releasing hormone, and WO 97/03066 discloses substituted benzolactam compounds as substance P antagonist. In fact that these quinoline compounds and substituted benzolactam compounds involve carbostyryl skeleton in their molecular structures. However, these compounds are quite different from the carbostyryl derivatives of the present invention

in both chemical structures and usages.

DISCLOSURE OF THE INVENTION

The present inventors have found the fact that at least one of the compound selected from the group consisting of carbostyryl derivatives represented by the general formula (1) and salts thereof including the above-mentioned known compounds possesses activities for inhibiting skin erythema (sunburn) and/or skin pigmentation. Such pharmaceutical activities could not been anticipated from the usefulnesses being disclosed in these prior art references. Thus the present invention has been successfully established on the basis of said finding.

The present invention relates to agents for inhibiting skin erythema (sunburn) and/or skin pigmentation containing, as the effective ingredient, at least one selected from the group consisting of carbostyryl derivatives and salts thereof represented by the general formula (1),



(wherein R¹ is a hydrogen atom, a lower alkyl group or a lower alkenyl group; R² is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranyloxy group; R³ and

R⁴ are the same or different from each other, and each is a lower alkyl group which may have hydroxyl groups as substituents; further R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional 5 nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered saturated heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoy group; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton 10 is a single bond or double bond).

Nowadays, vitamins such as vitamin E, ascorbic acid and the like; natural substances such as arbutin, kojic acid and the like are used as the effective ingredients in cosmetics for preventing sunburn and suntan 15 being caused by exposure to UV rays and the sun light, as well as for the purpose to effect bleaching the skin pigmentation such as spots and ephelides. However, these vitamins and natural substances are difficult to handle because they are unstable to oxygen, light, heat, alkalis 20 and acids. Also the effects for preventing sunburn and bleaching skin pigmentation performed by these vitamins and natural substances are not good enough.

Under such circumstances, it is expected and desired to develop a new compound which is stable to 25 oxygen, light, heat, alkalis and acids, also having excellent effects for preventing sunburn as well as for bleaching skin pigmentation. For the purpose to use such a new compound as an effective ingredient in quasi-drugs and

cosmetics which has to be applied to the human body for a long period of time, said new compound should not have any irritant action to the skin and highly safety to the skin without inducing cutaneous allergy. Also, such new 5 compound is desired not to give any adverse effect to the circulation system and central nervous system at the concentration in pharmaceutical applications.


The carbostyryl derivatives represented by the general formula (1) and salts thereof can entirely meet the 10 above-mentioned requirements. Thus, the carbostyryl derivatives and salts thereof of the present invention are stable to the light, heat, alkalis and acids and the like, as well as having excellent effects for preventing sunburn of the skin and for bleaching the skin pigmentation. 15 Furthermore, the carbostyryl derivatives and salts thereof of the present invention do not have any irritant action to the skin with highly safety to the skin without inducing cutaneous allergy. Additionally, the carbostyryl derivatives and salts thereof are easily soluble in water.

20 Similar to vitamin E, the carbostyryl derivatives and salts thereof of the present invention can scavenge diphenylpicrylhydrazide (DPPH) which is a model compound of lipoperoxide, and besides, the carbostyryl derivatives of the present invention can inhibit the formation of erythema 25 (sunburn) caused by irradiation of ultraviolet rays. Therefore, the carbostyryl derivatives and salts thereof of the present invention are useful as agents for preventing and treating various dermatopathies and dermatitises caused

by irradiation of ultraviolet rays, and by contact with oxygen radicals or lipoperoxides.

The carbostyryl derivatives and salts thereof of the present invention can be clearly inhibit the skin 5 pigmentation caused by irradiation of ultraviolet ray. Therefore, the carbostyryl derivatives and salts thereof of the present invention are useful as the active ingredient to be contained in cosmetics, quasi-drugs, pharmaceutical preparations and the like for preventing sunburn and suntan 10 caused by excessive exposures of ultraviolet rays and sun light, and for preventing and treating skin pigmentations such as spots and ephelides.

Among carbostyryl derivatives and salts thereof represented by the general formula (1), the carbostyryl 15 derivatives and salts thereof represented by the general formula (2),



(wherein R¹ is a hydrogen atom, a lower alkyl group or a lower alkenyl group; R² is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranloxy group; R³ and R⁴ are the same or different from each other, and each is a lower alkyl group which may have hydroxyl group as substituents; further R³ and R⁴ may form, together with the

adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered saturated heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and lower alkanoyl group; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond; provided that when both R³ and R⁴ are lower alkyl groups, then R² should be neither a hydrogen atom, a lower alkyl group nor a lower alkoxy group) are novel compounds which have not been known in any prior art literature.

Concrete examples of the substituents shown in the general formula (1) are as follows.

As to the lower alkyl groups, a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl groups and the like can be exemplified.

As to the lower alkenyl group, a straight-chain or branched-chain alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, 2-butenyl, 3-butenyl, 1-methylallyl, 2-pentenyl, 3-methyl-2-butenyl, 2-hexenyl groups and the like can be exemplified.

As to the lower alkoxy group, a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy groups and the like can be exemplified.

As to the alkenyloxy group, a straight-chain or branched-chain alkenyloxy group having 2 to 6 carbon atoms, such as vinyloxy, allyloxy, 2-butenyloxy, 3-butenyloxy, 1-methylallyloxy, 2-pentenyloxy, 3-methyl-2-butenyloxy, 5 2-hexenyloxy groups and the like can be exemplified.

As to the lower alkyl group which may have hydroxyl groups as substituents, a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, which may have 1 to 3 hydroxyl groups as substituents, such 10 as hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 2-hydroxyisopropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxypentyl, 3-hydroxypentyl, 4-hydroxypentyl, 5-hydroxypentyl, 2-hydroxyhexyl, 3-hydroxyhexyl, 4-hydroxyhexyl, 6-hydroxyhexyl, 1-methyl-2-hydroxyethyl, 1,1-dimethyl-2-hydroxyethyl, 1,2-dihydroxyethyl, 2,2-dihydroxyethyl, 1,3-dihydroxypropyl, 2,3-dihydroxypropyl, 1,2,3-trihydroxypropyl, 1,4-dihydroxybutyl, 2,4-dihydroxybutyl, 3,4-dihydroxybutyl, 1,2-dihydroxybutyl, 2,3-dihydroxybutyl, 1,3-dihydroxybutyl, 20 2,2-dihydroxybutyl, 1,2,3-trihydroxybutyl, 2,3,4-trihydroxybutyl, 2,3-dihydroxypentyl, 3,4-dihydroxypentyl, 3,5-dihydroxypentyl, 3,4,5-trihydroxypentyl, 2,4,5-trihydroxypentyl, 2,3-dihydroxyhexyl, 3,4-dihydroxyhexyl, 3,5-dihydroxyhexyl, 3,4,5-trihydroxyhexyl, 2,4,5-trihydroxyhexyl and the like can be exemplified.

As to the 5- or 6-membered saturated heterocyclic group which is formed by combining R³ and R⁴ to each other together with the adjacent nitrogen atom, further with or

without additional nitrogen atom, sulfur atom or oxygen atom, examples are pyrrolidinyl, piperidinyl, piperazinyl, morphorino, thiomorphorino groups and the like.

As to the above-mentioned heterocyclic group

5 having substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group, a heterocyclic group having 1 to 3 substituents selected from the group consisting of a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms and a straight-chain
10 or branched-chain alkanoyl group having 1 to 6 carbon atoms, there can be exemplified 4-methylpiperazinyl, 3,4-dimethylpiperazinyl, 3-ethylpyrrolidinyl, 2-propyl-pyrrolidinyl, 3,4,5-trimethylpiperidinyl, 4-butyl-piperidinyl, 3-pentylmorpholino, 4-hexylpiperazinyl, 3-
15 methylthiomorpholino, 4-formylpiperazinyl, 4-acetyl-piperazinyl, 4-acetyl piperidinyl, 3-propionylmorpholino, 2-butylthiomorpholino, 3-acetylpyrrolidinyl groups and the like.

As to the lower alkanoyl group, a straight-chain

20 or branched-chain alkanoyl group having 1 to 6 carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, tert-butylcarbonyl, hexanoyl groups can be exemplified.

The carbostyryl derivatives of the present

25 invention represented by the above-mentioned general formula (1) involve the following compounds as various embodiments.

1) A carbostyryl derivative represented by the above-

mentioned general formula (1) and salt thereof, wherein R¹ and R² are hydrogen atoms; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

2) A carbostyryl derivative represented by the above-

5 mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkyl group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

3) A carbostyryl derivative represented by the above-

10 mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkoxy group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

4) A carbostyryl derivative represented by the above-

15 mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkenyloxy group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

5) A carbostyryl derivative represented by the above-

20 mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkenyl group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

6) A carbostyryl derivative represented by the above-

25 mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a hydrogen atom; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

7) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ and R² are lower alkyl groups; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

5 8) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a lower alkoxy group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

10 9) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a lower alkenyloxy group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

15 10) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a lower alkenyl group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

20 11) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a hydrogen atom; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

25 12) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a lower alkyl group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups

as substituents.

- 13) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a lower alkoxy group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.
- 14) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a lower alkenyloxy group; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.
- 15) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ and R² are lower alkenyl groups; and R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.
- 16) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ and R² are hydrogen atoms; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.
- 17) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkyl group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further

with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

5 18) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkoxy group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur 10 atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

19) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkenyloxy group; and R³ and R⁴ may form a 5- or 6-membered heterocyclic group together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen 20 atom; said heterocyclic group may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

20) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a lower alkenyl group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group

which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

- 21) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a hydrogen atom; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which 10 may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.
- 22) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ and R² are lower alkyl groups; and R³ and R⁴ may form, 15 together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.
- 23) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a lower alkoxy group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur 25 atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

24) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a lower alkenyloxy group; and R³ and R⁴ may form a 5- or 6-membered heterocyclic group
5 together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom; said heterocyclic group may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

10 25) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a lower alkenyl group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur
15 atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

26) A carbostyryl derivative represented by the above-
20 mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a hydrogen atom; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group
25 which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

27) A carbostyryl derivative represented by the above-

mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a lower alkyl group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

28) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a lower alkoxy group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

29) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a lower alkenyloxy group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

30) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹

and R² are lower alkenyl groups; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have 5 substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group.

31) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a tetrahydropyranyloxy group; and 10 R³ and R⁴ are lower alkyl groups which may have hydroxyl group as the substituents.

32) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkyl group; R² is a tetrahydropyranyloxy group; 15 and R³ and R⁴ are lower alkyl groups which may have hydroxyl group as the substituents.

33) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a tetrahydropyranyloxy group; and R³ and R⁴ are lower alkyl groups which may have 20 hydroxyl group as the substituents.

34) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a hydrogen atom; R² is a tetrahydropyranyloxy group; and 25 R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group


consisting of a lower alkyl group and a lower alkanoyl group.

35) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ 5 is a lower alkyl group; R² is a tetrahydropyranyloxy group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected from the group 10 consisting of a lower alkyl group and a lower alkanoyl group.

36) A carbostyryl derivative represented by the above-mentioned general formula (1) and salt thereof, wherein R¹ is a lower alkenyl group; R² is a tetrahydropyranyloxy 15 group; and R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered heterocyclic group which may have substituents selected 20 from the group consisting of a lower alkyl group and a lower alkanoyl group.

The carbostyryl derivatives of the present invention represented by the general formula (1) can be prepared by various processes, and among of these processes, typical methods can be exemplified as the 25 following reaction formulae.

Reaction formula-1



(wherein R¹, R², R³, R⁴ and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined above; R⁵ is a hydrogen atom, a tetrahydro-pyranyl group or a lower alkanoyl group).

The reaction of a compound (3) with a compound (4) is carried out by reacting a compound (3), a compound (4) and formaldehyde in the presence or absence of an acid 10 in a suitable solvent.

As to the solvent used in this reaction, any solvent used for Mannich reaction can be used, for example water; alcohols such as methanol, ethanol, isopropanol and the like; alkanoic acids such as acetic acid and propionic acid and the like; acid anhydrides such as acetic anhydride and the like; polar solvents such as acetone, dimethyl-formamide and the like; or mixtures of these solvents can be exemplified.

As to the acid used in this reaction, mineral acids such as hydrochloric acid, hydrobromic acid and the like, organic acid such as acetic acid can be exemplified.

As to the formaldehyde used in this reaction, an aqueous solution containing 20 to 40% of formaldehyde.

trimer of formaldehyde, polymer of formaldehyde (paraformaldehyde) and the like can be suitably used.

A compound (4) may be used generally in an amount of at least an equimolar quantity, preferably an equimolar 5 to 5 times the molar quantity to one molar quantity of a compound (3). Further, formaldehyde may be used in an amount of at least an equimolar quantity, generally a large excess quantity to one molar quantity of a compound (3). Generally, this reaction is carried out suitably at 0 to 10 200 °C, preferably at room temperature to 150 °C, and the reaction is generally finished in about 0.5 to 15 hours.

In case of using a compound (3), wherein R⁵ is a tetrahydropyranyl group or a lower alkanoyl group, before adding formaldehyde to the reaction system, when R⁵ is a 15 lower alkanoyl group, then compound (3) is previously reacted with an excess amount of a compound (4) at 60 to 80 °C for 30 minutes to 2 hours; or when R⁵ is a tetrahydropyranyl group, then compound (3) is reacted with an acid at 60 to 80 °C for 30 minutes to 2 hours; so as to introduce 20 the compound (3) wherein corresponding R⁵ is converted into a hydrogen atom. Then compound (3) wherein R⁵ is a hydrogen atom is reacted under the reaction condition similar to the above-mentioned reaction of a compound (3) with a compound (4), by adding compound (4) and formaldehyde to the 25 reaction system.


In case of using a compound (3) wherein R⁵ is a tetrahydropyranyl group or a lower alkanoyl group, said compound (3) is subjected to hydrolysis to introduce to the

corresponding compound (3) wherein R⁵ is a hydrogen atom, then said compound (3) may be reacted with a compound (4). This hydrolysis is carried out in a suitable solvent or without solvent, and in the presence of an acid or basic 5 compound. As to the solvent used in this hydrolysis, examples are water; lower alcohols such as methanol, ethanol, isopropanol and the like; ketones such as acetone, methyl ethyl ketone and the like; ethers such as diethyl ether, dioxane, tetrahydrofuran, ethylene glycol dimethyl 10 ether and the like; fatty acids such as acetic acid, formic acid and the like; mixed solvents thereof can be exemplified. As to the acid used in this hydrolysis, mineral acids such as sulfuric acid, hydrochloric acid, hydrobromic acid and the like; organic acid such as formic acid, acetic 15 acid, aromatic sulfonic acid and the like can be exemplified. As to the basic compound, metal carbonates such as sodium carbonate, potassium carbonate and the like; metal hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide and the like can be exemplified. This 20 hydrolysis is carried out generally at about room temperature to 200 °C, preferably carried out at about room temperature to 150 °C, and is generally finished in about 10 minutes to 25 hours.

The reaction of a compound (3) with a compound 25 (5) is carried out in the presence of an acid, and in a suitable solvent or without solvent. As to the acid used in this reaction, mineral acids such as sulfuric acid, hydrochloric acid, hydrobromic acid and the like; organic

acids such as formic acid, acetic acid, acetic anhydride and the like can be exemplified. Among these acids, acetic anhydride is used preferably. As to the solvent, any one of the solvent used in the reaction of a compound (3) with 5 a compound (4) can also be used. The amount of a compound (5) is used at least an equimolar quantity, preferably an equimolar to 5 times the molar quantity thereof may be used to one molar quantity of a compound (3). This reaction is carried out generally at 0 to 150 °C, preferably proceeds at 10 room temperature to about 100 °C, and is finished generally within about 0.5 to 5 hours.

Reaction formula-2




(wherein R¹, R³, R⁴ and the carbon-carbon bond between 3-
15 and 4-positions in the carbostyryl skeleton are the same as
defined the above; R^{2a} is a lower alkenyl group or a lower
alkenyloxy group; R^{2b} is a lower alkyl group or a lower
alkoxy group).

Conversion of a compound (1a) to a compound (1b)
20 is carried out in a suitable solvent by a catalytic hydrogenation. As to the solvent used in this catalytic reduction, examples are water; acetic acid; alcohols such

as methanol, ethanol, isopropanol and the like; hydrocarbons such as hexane, cyclohexane and the like; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether and the like; esters such 5 as ethyl acetate, methyl acetate and the like; aprotic polar solvents such as N,N-dimethylformamide; and mixed solvents thereof can be exemplified. As to the catalysts for the catalytic hydrogenation, examples are palladium, palladium-black, palladium-carbon, platinum, platinum 10 oxide, copper chromite, Raney nickel and the like can be exemplified. Such catalyst may be used generally in an amount of 0.02 to 1 part per 1 part of the starting material. In carrying out of this reaction, an acid such as hydrochloric acid may be added in the reaction system. 15 The reaction temperature may be generally at about -20 to 150 °C, preferably as 0 to 100 °C, and the hydrogen gas pressure may be generally at 1 to 10 atmospheric pressure, and the reaction is generally finished in about 0.5 to 10 hours.

20 The compound (3) which is used as the starting material in the above-mentioned Reaction formula-1 is prepared, for example, by the following Reaction formula-3 and Reaction formula-4.

Reaction formula-3



(wherein R¹ and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined above; R⁶ is a lower alkanoyl group or tetrahydropyranyl group; R⁷ is a lower alkyl group or a lower alkenyl group; and X is a halogen atom).

The reaction of a compound (6) with a compound (7) is carried out generally in a suitable inert solvent, and in the presence of or absence of a basic compound. As to the inert solvent used in this reaction, examples are aromatic hydrocarbons such as benzene, toluene, xylene and the like; ethers such as tetrahydrofuran, dioxane, diethylelene glycol dimethyl ether and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like; lower alcohols such as methanol, ethanol, isopropanol, butanol, tert-butanol and the like; acetic acid, ethyl acetate, acetone, acetonitrile, pyridine, dimethyl sulfoxide, dimethylformamide, hexamethylphosphoryl triamide and the like; and mixed solvents thereof. As to the basic compound, examples are metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogen-

carbonate and the like; metal hydroxide such as sodium hydroxide, potassium hydroxide; sodium hydride, metallic potassium, metallic sodium, sodium amide; metal alcoholates such as sodium methylate, sodium ethylate and the like;


5 organic basic compounds such as pyridine, N-ethyl-diisopropylamine, dimethylaminopyridine, triethylamine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU), 1,4-diazabicyclo-[2.2.2]octane (DABCO) and the like can be exemplified.

10 The ratio of amount of a compound (6) to amount of a compound (7) is not specifically restricted and it may be selected from a wide range, thus at least an equimolar quantity, preferably an equimolar to about 10 times the molar quantity of the latter may be used to the former.

15 This reaction is carried out generally at 0 to about 200 °C, preferably 0 to about 170 °C, and is generally finished in about 30 minutes to 30 hours. Into this reaction system, a metal iodide such as sodium iodide, potassium iodide and the like may be added.

20 The reaction for introducing a compound (3a) to a compound (3b) is carried out under the condition similar to the hydrolysis of a compound (3) wherein R⁵ is a tetrahydropyranyl group or a lower alkanoyl group.

Reaction formula-4




(wherein R⁶, R⁷, X and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined in the above; and R^{1a} is a lower alkyl group or a lower alkenyl group).

The reaction of a compound (3c) with a compound (8) is carried out, for example in the presence of a basic compound and in a suitable solvent. As to the basic compound, sodium hydride, metallic potassium, metallic sodium, sodium amide, potassium amide and the like can be exemplified. As to the solvent, ethers such as dioxane, diethylene glycol dimethyl ether and the like can be exemplified; aromatic hydrocarbons such as toluene, xylene and the like; dimethylformamide, dimethyl sulfoxide, hexamethylphosphoryl triamide and the like can be exemplified. The ratio of amount of a compound (3c) to amount of a compound (8) is not specifically restricted and it can be selected from a wide range, and generally at least an equimolar quantity, preferably an equimolar to 2 times the molar quantity of the latter may be used to the former. This reaction is carried out generally at 0 to about 70 °C, preferably at 0 °C to about room temperature, and the

reaction is finished generally in 0.5 to about 12 hours.

Reaction formula-5




(wherein R^{1a}, R², R³, R⁴, X and the carbon-carbon bond

5 between 3- and 4-positions in the carbostyryl skeleton are the same as defined in the above).

The reaction of a compound (1c) with a compound (8) is carried out under the condition similar to that of employed in the reaction of a compound (3c) with a compound 10 (8) in the above-mentioned Reaction formula-4.

Reaction formula-6



(wherein R^1 , R^2 , R^3 and R^4 are the same as defined in the above).

15 The dehydrogenation of a compound (1) is carried out in a suitable solvent by using an oxidizing agent. As

to the oxidizing agent, benzoquinones such as 2,3-dichloro-5,6-dicyanobenzoquinone, chloranil (2,3,5,6-tetrachlorobenzoquinone) and the like; halogenating agents such as N-bromosuccinimide, N-chlorosuccinimide, bromine and the like; and dehydrogenating catalyst such as selenium dioxide, palladium-carbon, palladium-black, palladium oxide, Raney nickel and the like can be exemplified. Used amount of the halogenating agent is not specifically restricted and can be selected from a wide range, and generally 1 to 5 times the molar quantity, preferably 1 to 2 times the molar quantity of the halogenating agent may be used to the starting material. Further when the dehydrogenating catalyst is used, generally an excess amount of the catalyst may be used. As to the solvent, ethers such as dioxane, tetrahydrofuran, methoxymethanol, dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene, xylene, cumene and the like; halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like; alcohols such as butanol, amyl alcohol, hexanol and the like; polar protic solvents such as acetic acid; and polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, hexamethylphosphoryl triamide and the like can be exemplified. This reaction is carried out generally at room temperature to about 300 °C, preferably at room temperature to about 200 °C, and is completed generally in 1 to 40 hours.

For this reducing reaction of a compound (f), the

reaction conditions of a common catalytic reduction can be widely applied. As to the catalyst, metallic catalyst such as palladium, palladium-carbon, platinum, Raney nickel and the like can be exemplified. These metallic catalysts are used in general catalytic amount. As to the solvent, water; alcohols such as methanol, ethanol, isopropanol, and the like; ethers such as dioxane, tetrahydrofuran and the like; aliphatic hydrocarbons such as hexane, cyclohexane and the like; esters such as ethyl acetate and the like; and mixtures of these solvents can be exemplified. Said reducing reaction can be carried out either at an atmospheric pressure or under a pressurized condition, and generally may be carried out at an atmospheric pressure to about 20 kg/cm², preferably at an atmospheric pressure to about 10 kg/cm². The reaction may be carried out generally at temperature of about 0 to 150 °C, preferably at about room temperature to 100 °C.

Among carbostyryl derivatives represented by the general formula (1) according to the present invention, wherein a compound having acidic group can be converted into salt thereof by reacting it with a pharmaceutically acceptable basic compound. As to such basic compound, metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide and the like; alkali metal carbonates or bicarbonates such as sodium carbonate, sodium hydrogencarbonate and the like; alkali metal alcoholates such as sodium methylate, potassium ethylate and the like can be exemplified.

Further, among carbostyryl derivatives represented by the general formula (1) according to the present invention, wherein a compound having basic group can be converted into salt thereof easily by reacting it 5 with a pharmaceutically acceptable acid. As to such acid, inorganic acids such as sulfuric acid, nitric acid, hydrochloric acid, hydrobromic acid and the like: organic acids such as acetic acid, p-toluenesulfonic acid, ethanesulfonic acid, oxalic acid, maleic acid, citric acid, 10 succinic acid, benzoic acid and the like can be exemplified.

Additionally, the above-mentioned carbostyryl derivatives represented by the general formula (1) involve stereo isomers and optical isomers.

15 The desired carbostyryl derivatives prepared by the above-mentioned Reaction formulas can be isolated from the reaction systems by common separation methods and can be further purified, for example by distillation method, recrystallization method, column chromatography, ion- 20 exchange chromatography, gel chromatography, affinity chromatography, preparative thin-layer chromatography, solvent extraction method and the like can be applied.

Thus obtained carbostyryl derivatives of the present invention are used in the form of general types of 25 pharmaceutical compositions. Such pharmaceutical compositions are prepared by formulating with commonly used diluents such as fillers, bulking agents, binders, wetting agents, disint grators, surface active agents, lubricants

and the like, or excipients. Various forms of pharmaceutical compositions can be selected depend on the purpose for treating, and typical forms of the compositions including tablets, pills, powders, liquids, suspensions, 5 emulsions, granules, capsules, suppositories, injections (solutions and suspensions) and the like, and pharmaceutical compositions for external uses such as inhalants, nebulizing agents such as aerosol preparations for external use, further liquid paint preparations, lotions, gels, oily 10 ointments, emulsion type ointment basis such as O/W type hydrophylic ointments, and W/O type water absorbing ointments, water soluble ointment basis, creams, liniments, cataplasms, pastes, plasters, emulsions and the like, and sheet-form preparations can be exemplified.

15 For the purpose of shaping the pharmaceutical composition in the form of tablets, carriers which are known in this field can be used, for example excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline 20 cellulose, silicic acid and the like; binding agents such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl-cellulose, shelac, methylcellulose, calcium phosphate, polyvinylpyrrolidone and the like; disintegrators such as 25 dried starch, sodium alginate, agar-agar powder, laminaria powder, sodium hydrogencarbonate, calcium carbonate, esters of polyoxyethylenesorbitan fatty acid, sodium lauryl-sulfate, monoglyceride of stearic acid, starch, lactose and

the like; disintegration inhibitors such as white sugar, stearin, cacao butter, hydrogenated oils and the like; absorption accelerators such as quaternary ammonium base, sodium laurylsulfate and the like; wetting agents such as 5 glycerin, starch and the like; adsorbing agents such as starch, lactose, kaolin, bentonite, colloidal silicic acid and the like; and lubricants such as refined talc, stearic acid, boric acid powder, polyethylene glycols and the like can be used. Further, the tablets can be coated with 10 common coating materials to make them as sugar coated tablets, gelatin film coated tablets, tablets coated with enteric coatings, tablets coated with films or double layered tablets and multi-layered tablets.

For the purpose of shaping the pharmaceutical 15 composition in the form of pills, carriers which are known and widely used in this field can be used, for example, excipients such as glucose, lactose, starch, coconut butter, hydrogenated oils, kaolin, talc and the like; binders such as powdered gum arabic, powdered Tragacanth, 20 gelatin, ethanol and the like; disintegrators; such as laminaria, agar-agar are included.

For the purpose of shaping the pharmaceutical composition in the form of suppositories, carriers which are known and widely used in this field can be used, for 25 example, polyethylene glycols, coconut butter, higher alcohols, esters of higher alcohols, gelatin and semi-synthesized glycerides are included.

For the purpose of shaping the pharmaceutical

composition in the form of capsules, generally, the effective ingredient is mixed with the above-mentioned various carriers, then the mixture thus obtained is filled in hard capsules or soft capsules.

5 For the purpose of shaping the pharmaceutical composition in the form of injection preparations, a solution, an emulsion or a suspension of the effective ingredient is sterilized and is preferably made it isotonic to the blood. In making an injection preparation, whatever
10 carriers which are commonly used in this field can be applied. For example, water, ethyl alcohol, ethylene glycols, propylene glycols, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylenesorbitane fatty acid esters can be used. In these instances,
15 adequate amounts of sodium chloride, glucose or glycerin can be added to contain in the desired injection preparation for the purpose of having them isotonic. Furthermore, common dissolving agents, buffering agents, analgesic agents may be added. If necessary, coloring agents,
20 preservatives, perfumes, seasoning agents, sweetening agents and other medicines can be added into the desired preparations.

The amount of a compound of the general formula (1) and salt thereof to be contained in the pharmaceutical
25 preparations of the present invention is not specifically restricted and can be selected from a wide range, generally 1 to 70 % by weight of the compound may be contained in the whole composition.

Administration method of the pharmaceutical preparation of the present invention is not specifically restricted, thus it is administered by various methods depend on the type of administration form, the age of the patient, the distinction of sex, the condition of the symptoms and other factors. For example, tablets, pills, solutions, suspensions, emulsions, granules and capsules are administered orally. Injection preparations are administered intravenously singly or mixed with common injection transfusions, such as glucose solutions and amino acids solutions. If necessary, the injection preparations are administered singly intramuscularly, intracutaneously, subcutaneously or intraperitoneally. Suppositories are administered into the rectum. External preparations are administered by coating on the skin.

In case of using the carbostyryl derivatives of the present invention as to ingredients of cosmetics, they can be used in creams, lotions and oils for suntan or for protecting sunburn. In addition to the above, generally they are added as for UV-protecting agents and UV-inhibitors, or suntan agents and sunburn protecting agents.

Concretely, cosmetics can be exemplified such as face powder, cream, milk lotion, lotion, toilet water, toilet oil, bleaching agent and the like.

As to the forms of these cosmetics, liquid, oil, lotion, liniment, oily ointment base, emulsion-type ointment base such as O/W-type hydrophilic ointment base and W/O-type water absorbing ointment base, water-soluble

ointment base, paste, plaster, patch, cream, milk lotion and the like can be exemplified. These forms of cosmetics can be prepared by common and widely known methods of preparation.

5 For example, as to the ointment base, at least one oleaginous base can be used singly, or mixture of two or more of them can be used; or at least one water-soluble ointment base can be used singly, or mixture of two or more of them can be used.

10 Specific examples of these ointment base are fats and oils such as peanut oil, sesame oil, soybean oil, safflower oil, avocado oil, sunflower oil, corn oil, rapeseed oil, cotton seed oil, castor oil, camellia oil, coconut oil, olive oil, poppy seed oil, cacao butter, beef tallow, lard, wool fat and the like; modified bases obtained by subjecting these fats and oils to chemical changes such as hydrogenation; mineral oils such as petrolatum, paraffin, silicone oil, squalane and the like; higher fatty acid esters of isopropyl myristate, n-butyl myristate, isopropyl linoleate, propyl ricinolate, isopropyl ricinolate, isobutyl ricinoleate, heptyl ricinolate, diethyl sebacate, diisopropyl adipate; higher aliphatic alcohols such as cetyl alcohol and stearyl alcohol; and waxes such as bleached bees wax, spermaceti, Japan wax, lanolin, carnauba wax, shellac wax and the like; higher fatty acids such as stearic acid, oleic acid, palmitic acid and the like; mixtures of mono-, di- and triglycerides of saturated or unsaturated fatty acids having

12 to 18 carbon atoms; polyhydric alcohols such as ethylene glycol, polyethylene glycols, propylene glycols, polypropylene glycols, glycerin, batyl alcohol, pentaerythritol, sorbitol, mannitol and the like; gummy substances such as arabic gum, benzoin gum, guaiacum, tragacanth gum and the like; water-soluble natural high polymers such as gelatin, starch, casein, dextrin, pectin, sodium pectate, sodium alginate, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, nitrocellulose, crystalline cellulose and the like; water-soluble synthetic high polymers such as polyvinyl alcohols, poly(vinyl methyl ether), polyvinylpyrrolidone, sodium polyacrylate, carboxyvinyl polymer, polyethyleneimine and the like; non-ionic, anionic, amphoteric and cationic surface active agents; ethanol, isopropanol and water and the like can be exemplified.

In case of preparing the above-mentioned cosmetics, various types of the above-mentioned cosmetic

bases, for example excipients, binders, lubricants, disintegrators and the like can be used. Further, if necessary, various kinds of ingredients and additives for example, oily materials such as various kinds of fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps and the like; pharmacologically effective agents such as animal and vegetable extracts, vitamins, hormones, amino acids and the like can be used by suitably combined thereof. Thus obtained cosmetics can be

used by diluted further with water olive oil or a suitable solvent.

The amount of the carbostyryl derivatives of the general formula (1) or salts thereof to be contained in the 5 cosmetics of the present invention is not specifically restricted and can be selected from a wide range, and the amount may be generally selected within the range of 0.1 to 50% by weight in the whole composition.

The amount of using the pharmaceutical preparation or cosmetics of the present invention containing the carbostyryl derivative of the general formula (1) of the present invention as the effective ingredient is suitably selected depend on the administration method, the age of the patient, the distinction of sex and related other 15 conditions, the degree of disease condition of the patient.

In case of using as pharmaceutical preparation, the amount the effective ingredient may be administered about 0.6 to 50 mg per 1 kg of the body weight per day, and in case of using as cosmetics, the amount of the effective inredient 20 may be administered about 0.1 to 30 mg per 1 kg of the body weight per day. These pharmaceutical preparation or cosmetics can be divided for administration purpose in 2 to 4 times a day.

EXAMPLES

25 The present invention will be explained in more detail by illustrating Reference examples, Examples and Pharmacological tests as follows.

Reference example 1

65 Grams of 5-acetoxy-3,4-dihydro-8-hydroxy-2(1H)-quinolinone was dissolved in 500 ml of dimethylformamide (DMF), to this solution were added 52 g of 5 potassium carbonate powder and 50 ml of allyl bromide, the mixture thus obtained was stirred at room temperature for 8 hours. To this reaction mixture was diluted with 500 ml of water, extracted with 2 liter of ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate, then concentrated to dryness under reduced pressure. The residue was recrystallized from ethanol, there was obtained 70 g of 5-acetoxy-8-allyloxy-3,4-dihydro-2(1H)-quinolinone as brown needle-like crystals.

15 Melting point: 137-139 °C.

Reference example 2

9 Grams of 5-acetoxy-8-allyloxy-3,4-dihydro-2(1H)-quinolinone was dissolved in 100 ml of DMF, 1.51 g of 60%-sodium hydride was added gradually in limited amounts to this solution, this reaction mixture was stirred at room temperature until generation of hydrogen gas ceased. Under stirring and ice-cooling conditions, 100 ml of water was added to this reaction mixture, extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate, the dried extract was concentrated under reduced pressure. The oily product thus obtained was purified by a silica gel column chromato-

graphy, there was obtained 7 g of 5-acetoxy-8-allyloxy-3,4-dihydro-1-methyl-2(1H)-quinolinone as pale yellow oily product.

¹H-NMR (CDCl₃) δ ppm:

5 2.30 (3H, s), 2.52 (2H, dd), 2.65 (2H, dd),
 3.40 (3H, s), 4.51-4.55 (2H, m),
 5.29 (1H, dd), 5.39 (1H, dd), 5.96-6.11
 (1H, m), 6.76 (1H, d), 6.80 (1H, d).

Reference example 3

10 6 Grams of 5-hydroxy-3,4-dihydro-8-allyloxy-2(1H)-quinolinone was dissolved in 20 ml of dihydropyran, to this solution was added 2 ml of concentrated hydrochloric acid, then refluxed by heating for 1 hour. To this reaction mixture was added 5 g of potassium carbonate powder and stirred, then concentrated under reduced pressure. The residue thus obtained was extracted with ethyl acetate, the extract was washed with water, dried over anhydrous magnesium sulfate, again concentrated under reduced pressure to obtain pale yellow oily product. A mixed solvent of ethyl acetate-n-hexane was added to the oily product and allowed to stand for crystallization. There was obtained 8 g of 5-tetrahydropyranloxy-8-allyloxy-3,4-dihydro-2(1H)-quinolinone as white amorphous product.

25 Melting point: 111-113 °C.

Reference example 4

7 Grams of 5-tetrahydropyranyloxy-8-allyloxy-3,4-dihydro-2(1H)-quinolinone was dissolved in 50 ml of DMF, then 1 g of 60%-sodium hydride was added gradually in limited amounts to this solution, the reaction mixture was stirred at room temperature until generation of hydrogen gas ceased. To this reaction mixture was added 2.7 g of prenyl chloride, stirred at room temperature for 8 hours. To this mixture was added 100 ml of water and stirred, the mixture was acidified by adding concentrated hydrochloric acid, stirred at 60 °C for 1 hour to remove the tetrahydropyranyl group at 5-position. The mixture was extracted with ethyl acetate, and washed with water, dried over anhydrous magnesium sulfate, then concentrated under reduced pressure. The oily product thus obtained was purified by a silica gel column chromatography, there was obtained 4.2 g of 5-hydroxy-8-allyloxy-3,4-dihydro-1-prenyl-2(1H)-quinolinone as pale yellow oily product.

¹H-NMR (CDCl₃) δ ppm:
1.60 (6H, s), 2.52 (2H, dd), 2.80 (2H, dd), 4.42-4.62 (2H, m), 5.13 (1H, t), 5.24 (1H, dd), 5.35 (1H, dd), 5.96-6.11 (1H, m), 6.80 (1H, d), 6.69 (1H, d).

Reference example 5

10 Grams of 5-acetoxy-8-hydroxy-2(1H)-quinolinone was dissolved in 100 ml of DMF, to this solution was added 14 g of potassium carbonate and 9 ml of allyl bromide,

stirred at room temperature for 8 hours. Under ice-cooling and stirring conditions, the reaction mixture was acidified by adding hydrochloric acid, this mixture was diluted by adding 200 ml of water. The mixture was extracted with 500 ml of ethyl acetate, the extract was washed with water, dried over anhydrous magnesium sulfate, then concentrated to dryness under reduced pressure. The residue thus obtained was recrystallized from a mixed solvent of ethyl acetate-n-hexane, there was obtained 9.8 g of 5-acetoxy-8-allyloxy-2(1H)-quinolinone as pale yellow needle-like crystals.

Melting point: 142-143 °C.

Reference example 6

9.16 Grams of 5-acetoxy-8-tetrahydropyranloxy-3,4-dihydro-2(1H)-quinolinone was dissolved in 200 ml of methanol, to this solution was added 45 ml of an aqueous solution of 10%-potassium carbonate, refluxed by heating for 1 hour, then concentrated to dryness under reduced pressure, there was obtained 5-hydroxy-8-tetrahydro-pyranloxy-3,4-dihydro-2(1H)-quinolinone. This product was suspended in 100 ml of DMF, further 4.1 g of potassium carbonate was added to this suspension and stirred. To this mixture was added 3 ml of allyl bromide at room temperature and stirred for 8 hours. To this reaction mixture was added 200 ml of water, and extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate, concentrated under reduced

pressure. The residue was recrystallized from ethyl acetate-n-hexane, there was obtained 6 g of 8-tetrahydro-pyranloxy-5-allyloxy-3,4-dihydro-2(1H)-quinolinone as white solid product.

5 Melting point: 113-115 °C.

Example 1

1.5 Grams of 5-acetoxy-3,4-dihydro-8-methoxy-2(1H)-quinolinone was suspended in 10 ml of ethanol, to this suspension were added 4 ml of 50%-dimethylamine aqueous solution and 2 ml of 37%-formalin, this mixture was refluxed by heating for 10 hours. The reaction mixture was concentrated to dryness under reduced pressure, the residue was purified by a silica gel flash column chromatography (eluent: methylene chloride: methanol=20:1→10:1). The oily product thus obtained was dissolved in ethanol, this solution was acidified by adding hydrochloric acid, concentrated to dryness, and recrystallized from ethanol, there was obtained 3.8 g of 6-(dimethylaminomethyl)-3,4-dihydro-5-hydroxy-8-methoxy-2(1H)-quinolinone hydrochloride as white powdery product.

Melting point: 210-212 °C (decomposed)

¹H-NMR (DMSO-d₆) δ ppm:
2.42 (2H, t), 2.70 (6H, s), 2.88 (2H, t),
3.76 (3H, s), 4.22 (2H, s), 7.07 (1H, s),
25 8.89 (1H, s), 9.12 (1H, s), 10.20 (1H, s).

Example 2

16.7 Grams of 5-hydroxy-3,4-dihydrocarbostyryl was suspended in 300 ml of water, 20 ml of diethylamine was added thereto and stirred. To this mixture were added 20 5 ml of an aqueous solution of 37%-formalin, and stirred at room temperature for 2 hours. Precipitated crystals were collected by filtration, washed with water and dried. Recrystallized from ethanol, there was obtained 18 g of needle-like crystals, which was determined as 6-diethyl-10 aminomethyl-5-hydroxy-3,4-dihydrocarbostyryl by means of an X-ray crystal structure analysis.

Melting point: 161-162 °C.

$^1\text{H-NMR}$ (CDCl_3) δ ppm:

15 1.61 (6H, t), 2.58-2.65 (6H, m),
 2.93 (2H, t), 3.73 (2H, s), 6.23 (1H, d),
 6.75 (1H, d), 8.44 (1H, s).

Example 3

16.3 Grams of 6-hydroxy-2(1*H*)-quinolinone was suspended in 300 ml of ethanol, under stirring 14.4 g of 20 pyrrolidine and 20 ml of 37%-formalin were added to this suspension, this mixture was refluxed by heating for 12 hours. Precipitated crystals were filtered, washed with cold ethanol and dried. The dried crystals were dissolved in ethanol and the ethanol solution was acidified with 25 hydrochloric acid, concentrated to dryness under reduced pressure. Recrystallized from water, there was obtained 13 g of 6-hydroxy-5-(1-pyrrolidinyl)methyl-2(1*H*)-quinolinone

hydrochloride as pale yellow needle-like crystals.

Melting point: 242-243 °C.

¹H-NMR (DMSO-d₆) δ ppm:

1.8-2.02 (4H, m), 3.10-3.30 (2H, m),

5 3.43 (4H, br.s), 4.60 (2H, d), 6.54 (1H, d),
7.32 (2H, s), 8.29 (1H, d), 10.12 (1H, br.s).

Example 4

5.2 Grams of 8-allyloxy-5-acetoxy-3,4-dihydro-2(1H)-quinolinone was dissolved in 20 ml of ethanol, under
10 stirring, to this solution were added 10 ml of 50%-dimethylamine aqueous solution and 10 ml of 37%-formalin solution, this mixture was stirred at 70 °C for 8 hours. After cooled, the reaction mixture was concentrated to dryness, extracted with ethyl acetate, and the extract was
15 washed with water and concentrated to dryness, the residue was purified by a silica gel column chromatography (eluent: methylene chloride: methanol=20:1→10:1). The crude crystals were dissolved in ethanol, and acidified with hydrochloric acid then concentrated to dryness. The
20 residue was recrystallized from ethanol, there was obtained 3.8 g of 8-allyloxy-3,4-dihydro-5-hydroxy-6-dimethylaminomethyl-2(1H)-quinolinone hydrochloride as white powdery product.

Melting point: 184-186 °C (decomposed).

25 ¹H-NMR (DMSO-d₆) δ ppm:

2.43 (2H, t), 2.69 (6H, s), 2.83 (2H, t),

4.20 (2H, s), 4.53 (2H, d), 5.24 (1H, dd),

5.43 (1H, dd), 5.96-6.11 (1H, m),
7.11 (1H, s), 8.94 (1H, s), 9.06 (1H, s),
10.18 (1H, br).

Example 5

5 41 Grams of 8-allyloxy-3,4-dihydro-5-hydroxy-
2(1H)-quinolinone was dissolved in 500 ml of ethanol, under
stirring 30 ml of piperidine and 30 ml of 37%-formalin were
added to this solution, this mixture was stirred at 70 °C
for 4 hours. After cooled, the reaction mixture was
10 concentrated to dryness, extracted with 1 liter of
methylene chloride, the extract was washed with water and
dried, again concentrated to dryness. The residue was
purified by a silica gel column chromatography (eluent:
methylene chloride: ethyl acetate=20:1). The purified
15 product was recrystallized from ethyl acetate, there was
obtained 61g of 8-allyloxy-3,4-dihydro-5-hydroxy-6-(1-
piperidinyl)methyl-2(1H)-quinolinone.

Melting point: 144-145 °C.

Example 6

20 61 Grams of 8-allyloxy-3,4-dihydro-5-hydroxy-6-
(1-piperidinyl)methyl-2(1H)-quinolinone was suspended in
50% ethanol aqueous solution, the suspension was acidified
by adding a concentrated hydrochloric acid, then crystals
were precipitated immediately. Allowed to stand for a
25 while, the crystals precipitated were collected by filtra-
tion, washed with ice-cooled ethanol and dried. The dried

crystals were recrystallized from ethanol, there was obtained 40 g of 8-allyloxy-3,4-dihydro-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone hydrochloride as pale yellow needle-like crystals.

5 Melting point: 216-220 °C (decomposed).

¹H-NMR (DMSO-d₆) δ ppm:

1.12-1.95 (6H, m), 2.43 (2H, t),
2.75-3.00 (4H, br), 3.27 (2H, br),
4.17 (2H, s), 4.56 (2H, d), 5.24 (1H, dd),
10 5.44 (1H, dd), 6.02-6.17 (1H, m),
7.15 (1H, s), 8.85 (1H, s), 9.03 (1H, s),
10.18 (1H, br).

Example 7

5 Grams of 8-allyloxy-3,4-dihydro-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone hydrochloride which was obtained in Example 6, was dissolved in 200 ml of ethanol, to this solution was added 200 mg of 5%-palladium-carbon, and carried out reduction at 3 kg/cm² of hydrogen pressure at room temperature. The catalyst was removed by filtration, and the filtrate was concentrated to dryness. Residue thus obtained was recrystallized from ethanol, there was obtained 2.8 g of 3,4-dihydro-8-propyloxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone hydrochloride as a white powder.

25 Melting point: 221-224 °C (decomposed).

¹H-NMR (DMSO-d₆) δ ppm:

0.99 (3H, t), 1.25-1.90 (8H, m), 2.43 (2H, t),
 2.80-3.01 (4H, m), 3.85-4.00 (6H, m),
 4.17 (2H, d), 5.24 (1H, dd), 5.35 (1H, dd),
 5 5.96-6.11 (1H, m), 7.11 (1H, s), 8.82 (1H, s),
 8.97 (1H, s), 10.21 (1H, s).

Example 8

8-Tetrahydropyranloxy-5-allyloxy-3,4-dihydro-2(1H)-quinolinone which was obtained in Reference example 10 6, piperidine and 37%-formalin were reacted similarly as in Example 5, there was obtained 5-allyloxy-3,4-dihydro-8-hydroxy-7-(1-piperidinyl)methyl-2(1H)-quinolinone. Next, this compound was treated similarly as in Example 6 and recrystallized from ethanol, there was obtained 5-allyloxy-15 3,4-dihydro-8-hydroxy-7-(1-piperidinyl)methyl-2(1H)-quinolinone hydrochloride as a white powder.

Melting point: 181-186 °C (decomposed).

¹H-NMR (DMSO-d₆) δ ppm:


1.30-1.85 (6H, m), 2.43 (2H, t), 2.80-3.00
 20 (4H, m), 3.34 (2H, br), 4.19 (2H, s),
 4.54 (2H, d), 5.27 (1H, dd), 5.43 (1H, dd),
 6.05-6.20 (1H, m), 6.85 (1H, s), 8.91 (1H, s),
 9.29 (1H, s), 9.90 (1H, br).

Examples 9 - 47

25 By using suitable starting materials and procedures similar to those employed in Examples 1 - 5 and 8,

there were obtained compounds of Examples 9 - 47 shown in Tables 1 - 10 as follows.

Table 1



Compound of Example 9

R¹: H R²:-CH₃ (8-position) R³:-C₂H₅ R⁴:-C₂H₅

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless granular

Recrystallization solvent: Ethyl acetate NMR (1)

Melting point: 146-147 °C. Form: Free base

Compound of Example 10

R¹: H R²:-CH₃ (6-position) R³:-C₂H₅ R⁴:-C₂H₅

OH: at 5-position

-CH₂NR³R⁴: at 8-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethyl acetate NMR (2)

Melting point: 133-134 °C. Form: Free base

Table 2

Compound of Example 11

R^1 : H R^2 : -CH₃ (8-position) R^3 : -CH₃ R^4 : -CH₃

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Double bond

Crystal form: Colorless needle-like

Recrystallization solvent: Ethanol NMR (3)

Melting point: 196-206 °C. Form: Free base

Compound of Example 12

R^1 : H R^2 : -CH₃ (8-position) R^3 : -CH₃ R^4 : -CH₃

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 217-219 °C. Form: HCl salt

Compound of Example 13

R^1 : H R^2 : H R^3 : -C₂H₅ R^4 : -C₂H₅

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless flake

Recrystallization solvent: Ethyl acetate-n-hexane

Melting point: 161-162 °C.

Form: Free base

Table 3

Compound of Example 14

 $R^1: H \quad R^2: H$ $R^3: -CH_3 \quad R^4: -CH_3$

OH: at 5-position

 $-CH_2NR^3R^4:$ at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless flake

Recrystallization solvent: Ethyl acetate-n-hexane

Melting point: 189-191 °C.

NMR (4)

Form: HCl-salt

Compound of Example 15

 $R^1: H \quad R^2: H$ $R^3: -CH_3 \quad R^4: -CH_3$

OH: at 6-position

 $-CH_2NR^3R^4:$ at 7-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 229-230 °C. (decomp.)

Form: HCl-salt

Compound of Example 16

 $R^1: H \quad R^2: -CH_3$ (7-position) $R^3: -CH_3 \quad R^4: -CH_3$

OH: at 6-position

 $-CH_2NR^3R^4:$ at 5-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder


Recrystallization solvent: Ethanol

Melting point: 238-239 °C. (decomp.)

Form: HCl-salt

Table 4

Compound of Example 17



OH: at 6-position

$-\text{CH}_2\text{NR}^3\text{R}^4$: at 5-position


Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol NMR (5)

Melting point: 198-205 °C.(decomp.) Form: HCl-salt

Compound of Example 18



OH: at 5-position

$-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position


Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 184-186 °C.(decomp.) Form: HCl-salt

Compound of Example 19



OH: at 5-position

$-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless needle-like

Recrystallization solvent: Ethanol-diethyl ether

Melting point: 194-196 °C.(decomp.) Form: HCl-salt

Table 5

Compound of Example 20

R^1 : $-CH_3$ R^2 : $-OCH_2CH=CH_2$ (8-position) R^3 : $-CH_3$ R^4 : $-CH_3$

OH: at 5-position

$-CH_2NR^3R^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Acetone

Melting point: 170-172 °C. Form: HCl-salt

Compound of Example 21

R^1 : H R^2 : H R^3 and R^4 : $-N$ 

OH: at 5-position

$-CH_2NR^3R^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless granular

Recrystallization solvent: Ethyl acetate NMR (6)

Melting point: 207-217 °C. Form: Free base

Compound of Example 22

R^1 : H R^2 : H R^3 and R^4 : $-N$ 

OH: at 6-position

$-CH_2NR^3R^4$: at 5-position

Bond between 3- and 4-positions: Double bond

Crystal form: Pale yellow powder

Recrystallization solvent: Water

Melting point: 242-243 °C. Form: HCl-salt

Table 6

Compound of Example 23

R^1 : H R^2 : $-CH_2CH=CH_2$ (7-position) R^3 and R^4 : $-N$ 

OH: at 6-position

$-CH_2NR^3R^4$: at 5-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Isopropyl alcohol NMR (7)

Melting point: 240-250 °C.(decomp.) Form: HCl-salt

Compound of Example 24

R^1 : $-CH_2CH-CH_3$, R^2 : $-CH_2CH=CH_2$ (7-position)

 |

 CH₃

R^3 and R^4 : $-N$ 

OH: at 6-position

$-CH_2NR^3R^4$: at 5-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 172-174 °C Form: HCl-salt

Compound of Example 25

R^1 : H R^2 : -CH₃ (6-position) R^3 and R^4 : $-N$ 

OH: at 7-position

$-CH_2NR^3R^4$: at 8-position

Bond between 3- and 4-positions: Single bond


Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 225-227 °C (decomp.) Form: HCl-salt

Table 7

Compound of Example 26

R^1 : H R^2 : -CH₃ (8-position) R^3 and R^4 : 

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond


Crystal form: Colorless plate

Recrystallization solvent: Ethyl acetate

Melting point: 226-231 °C.

Form: Free base

Compound of Example 27

R^1 : H R^2 : -CH₃ (8-position) R^3 and R^4 : 

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Double bond


Crystal form: Colorless needle-like

Recrystallization solvent: Ethanol-water NMR (8)

Melting point: 234-260 °C (decompd.)

Form: HCl-salt

Compound of Example 28

R^1 : H R^2 : -OCH₂CH=CH₂ (8-position) R^3 and R^4 : 

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Pale yellow needle-like

Recrystallization solvent: Ethanol NMR (9)

Melting point: 216-220 °C (decompd.)

Form: HCl-salt

Table 8

Compound of Example 29

R^1 : H R^2 : $-OCH_2CH=CH_2$ (8-position) R^3 and R^4 : 

OH: at 5-position

$-CH_2NR^3R^4$: at 6-position

Bond between 3- and 4-positions: Double bond

Crystal form: Pale yellow needle-like

Recrystallization solvent: Ethanol

Melting point: 205-207 °C (decompd.)

Form: HCl-salt

Compound of Example 30

R^1 : H R^2 : $-O(CH_2)_2CH_3$ (8-position) R^3 and R^4 : 

OH: at 5-position

$-CH_2NR^3R^4$: at 6-position

Bond between 3- and 4-positions: Single bond


Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 221-224 °C (decompd.)

Form: HCl-salt

Compound of Example 31

R^1 : $-CH_3$ R^2 : $-OCH_2CH=CH_2$ (8-position) R^3 and R^4 : 

OH: at 5-position

$-CH_2NR^3R^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder



Recrystallization solvent: Ethyl acetate

Melting point: 164-167 °C.

Form: HCl-salt

Table 9

Compound of Example 32



OH: at 5-position

 $-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless flake

Recrystallization solvent: Petroleum ether

Melting point: 77-79 °C. Form: Free base

Compound of Example 33



OH: at 5-position

 $-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless flake

Recrystallization solvent: Ethanol

Melting point: 178-179 °C. Form: Free base

Compound of Example 34



OH: at 5-position

 $-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 218-220 °C. Form: HCl-salt

Table 10

Compound of Example 35

R^1 : H R^2 : -OCH₃ (8-position) R^3 : -CH₃ R^4 : -CH₃

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 210-212 °C. Form: HCl-salt

Compound of Example 36

R^1 : H R^2 : H R^3 : -CH₃ R^4 : -CH₃

OH: at 7-position

-CH₂NR³R⁴: at 6-position



Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 161-163 °C. Form: HCl-salt

Compound of Example 37



OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: n-Hexane

Melting point: 79-81 °C. Form: Free base

Table 11

Compound of Example 38

R^1 : H R^2 : -OCH₂CH=CH₂ (5-position) R^3 and R^4 : 

OH: at 8-position

-CH₂NR³R⁴: at 7-position


Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 183-186 °C. Form: HCl-salt

Compound of Example 39

R^1 : H R^2 : -OCH₂CH=CH₂ (8-position) R^3 and R^4 : 

OH: at 5-position

-CH₂NR³R⁴: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 209-211 °C. Form: HCl-salt

Compound of Example 40

R^1 : H R^2 : -OCH₂CH=CH₂ (6-position) R^3 : -C₂H₅ R^4 : -C₂H₅

OH: at 5-position

-CH₂NR³R⁴: at 8-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethanol

Melting point: 179-183 °C. (decompd.)

Form: HCl-salt

Table 12

Compound of Example 41

$R^1: H \quad R^2: -(CH_2)CH_3$ (6-position) R^3 and $R^4: -N$

OH: at 5-position

$-CH_2NR^3R^4:$ at 8-position


Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethyl acetate

Melting point: 162-163 °C.

Form: Free base



Compound of Example 42

$R^1: H \quad R^2: -OCH_2CH=CH_2$ (8-position) R^3 and $R^4: -N$

OH: at 5-position

$-CH_2NR^3R^4:$ at 6-position


Bond between 3- and 4-positions: Single bond

Crystal form: Pale brown plate

Recrystallization solvent: Ethyl acetate-n-hexane

Melting point: 122-123 °C.

Form: Free base



Compound of Example 43

$R^1: H \quad R^2: -OCH_2CH=CH_2$ (8-position) $R^3: -CH_2CH_2OH$

OH: at 5-position $R^4: -CH_2CH_2OH$

$-CH_2NR^3R^4:$ at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless needle-like

Recrystallization solvent: Ethyl acetate-n-hexane

Melting point: 106.2 °C.

Form: Free base

Table 13

Compound of Example 44

R^1 : H R^2 : $-OCH_2CH=CH_2$ (8-position) R^3 : $-CH_2CH_2OH$

$-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: Colorless needle-like


Recrystallization solvent: Ethyl acetate-n-hexane

Melting point: 86-87 °C. Form: Free base

Compound of Example 45

R¹: H R²: -OCH₂CH=CH₂ (8-position)

OH: at 5-position



$-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethyl acetate

Melting point: 184-186 °C. Form: Free base

Compound of Example 46

$$R^1: H \quad R^2: -O-\text{cyclohexyl} \quad (\text{8-position}) \quad R^3: -CH_3 \quad R^4: -CH_3$$

OH: at 5-position

$-\text{CH}_2\text{NR}^3\text{R}^4$: at 6-position

Bond between 3- and 4-positions: Single bond


Crystal form: White powder

Recrystallization solvent: Ethyl acetate

Melting point: 152-153 °C. Form: Free base

Table 14

Compound of Example 47



OH: at 5-position

$-\text{CH}_2\text{NR}^3\text{R}^4:$ at 6-position

Bond between 3- and 4-positions: Single bond

Crystal form: White powder

Recrystallization solvent: Ethyl acetate

Melting point: 136-137 °C. Form: Free base

NMR spectra of compounds (1) - (9) in Examples 9, 10, 11, 14, 17, 21, 23, 27 and 28 are:

(1) $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.10 (6H, t), 2.10 (3H, s), 2.55-2.65 (6H, m),
 5 2.94 (2H, t), 3.68 (2H, s), 6.62 (1H, s),
 7.26 (1H, s).

(2) $^1\text{H-NMR}$ (CDCl_3) δ ppm:

1.04 (6H, t), 2.18 (3H, s), 2.48 (4H, q),
 10 2.56 (2H, t), 2.93 (2H, t), 3.53 (1H, br),
 6.70 (1H, s), 10.25 (1H, s).

(3) $^1\text{H-NMR}$ (CDCl_3) δ ppm:

2.31 (3H, s), 2.34 (6H, s), 3.64 (2H, s),
 6.55 (1H, d), 6.89 (1H, s), 8.17 (1H, d),
 9.68 (1H, br).

15 (4) $^1\text{H-NMR}$ (DMSO-d_6) δ ppm:

1.60 (6H, s), 2.52 (2H, dd), 2.80 (2H, dd),
 4.42-4.46 (2H, m), 5.13 (1H, t), 5.24 (1H, dd),

5.35 (1H, dd), 5.96-6.11 (1H, m), 6.60 (1H, d),
6.69 (1H, d).

(5) $^1\text{H-NMR}$ (DMSO-d₆) δ ppm:

1.66 (3H, s), 1.76 (3H, s), 2.22 (3H, s),
5 2.51 (2H, t), 2.74 (6H, s), 2.92 (2H, t),
3.35 (2H, s), 4.33 (2H, d), 5.04 (1H, t),
6.88 (1H, s), 8.98 (1H, s), 9.87 (1H, br).

(6) $^1\text{H-NMR}$ (CDCl₃) δ ppm:

1.40-1.50 (6H, m), 2.15-2.80 (6H, m),
10 2.94 (2H, t), 3.60 (2H, s), 6.35 (1H, d),
6.74 (1H, d), 8.58 (1H, s), 9.96 (1H, br).

(7) $^1\text{H-NMR}$ (DMSO-d₆) δ ppm:

1.80-2.15 (4H, m), 2.43 (2H, t), 3.05-3.36
(4H, m), 5.02 (1H, dd), 5.09 (1H, dd),
15 5.83-5.99 (1H, m), 6.71 (1H, s), 8.76 (1H, s),
9.90 (1H, s), 10.19 (1H, br).

(8) $^1\text{H-NMR}$ (DMSO-d₆) δ ppm:

1.25-1.85 (6H, m), 2.32 (3H, s), 2.91 (2H, br),
3.36 (2H, br), 4.29 (2H, s), 6.48 (1H, d)
20 7.44 (1H, s), 8.25 (1H, d), 10.9 (1H, br)
10.85 (1H, s).

(9) $^1\text{H-NMR}$ (DMSO-d₆) δ ppm:

1.12-1.95 (6H, m), 2.43 (2H, t), 2.75-3.00
(4H, br), 3.27 (2H, br), 4.17 (2H, s),
25 4.56 (2H, d), 5.24 (1H, dd), 5.44 (1H, dd),
6.02-6.17 (1H, m), 7.15 (1H, s), 8.85 (1H, s)
9.03 (1H, s), 10.18 (1H, br).

Pharmaceutical preparation example 1

5-Hydroxy-6-diethylaminomethyl-8-methyl-

3,4-dihydro-2(1H)-quinolinone

(compound of the present invention) 5 mg

5	Starch	132 mg
	Magnesium stearate	18 mg
	<u>Lactose</u>	<u>45 mg</u>
Total		200 mg

By using a conventional procedure, each tablet
 10 containing the above-mentioned formulation was prepared.

Pharmaceutical preparation example 2

5-Hydroxy-6-(1-piperidinyl)methyl-8-
allyloxy-2(1H)-quinolinone

(compound of the present invention) 500 mg

15	Polyethylene glycol (M.W. 4,000)	0.3 g
	Sodium chloride	0.9 g
	Polyoxyethylene sorbitan monooleate	0.4 g
	Sodium metabisulfite	0.1 g
	Methyl paraben	0.18 g
20	Propyl paraben	0.02 g
	<u>Distilled water for injection</u>	<u>100 ml</u>

The above mentioned parabens, sodium
 metabisulfite and sodium chloride were dissolved in the
 above-mentioned distilled water at 80 °C under stirring.

25 The solution thus obtained was cooled to 40 °C, then the
 compound of the present invention, polyethylene glycol and
 polyoxyethylene sorbitan monooleate were dissolved therein

in this order. The volume of this solution was adjusted to the final volume by adding distilled water for injection, then the solution was subjected to sterile filtration by using a suitable filter paper. 1 ml each of the solution 5 thus obtained was filled in an ampoule separately to make injection preparation.

Pharmacological tests

Pharmacological tests of carbostyryl derivatives represented by the general formula (1) of the present 10 invention were conducted by test methods as explained below with the following results.

(1) DPPH free radical extinction activity test

The test was conducted by procedures according to the method by Marsden S. Blois [Nature, Vol. 26, 1199-1200, 15 (1958)].

Into 0.5 ml of 200 mM of acetic acid buffer solution (pH 5.5) were added 0.5 ml of distilled water, 0.5 ml of ethanol and 5 μ l of 10 mM of the test compound solution (an ethanol solution, a dimethylformamide solution 20 or an aqueous solution), and stirred at 30 °C for 5 minutes. To this mixed solution was added 1.5 ml of an ethanol solution of 250 μ M of 1,1-diphenyl-2-picrylhydrazyl (DPPH), this mixture was incubated at 30 °C for 30 minutes. After 25 the incubation, the optical absorbance (at 517 nm) of this reaction mixture was measured, and the number of captured free radicals of DPPH was calculated from the ratio of optical absorbance of test compound and that of α -

tocopherol (standard substance: the number of captured free radicals: 2) by the following formula:

Number of captured free radicals

of DPPH performed by test sample = [(A) × 2]/(B)

5 [wherein (A): optical absorbance of the test sample, and
(B): optical absorbance of α -tocopherol].

The test results are shown in Table 15.

Table 15

Test compound	Number of captured free radicals of DPPH
Compound of Example 9	1
Compound of Example 13	1
Compound of Example 18	1.5
Compound of Example 22	1.5
Compound of Example 23	3
Compound of Example 25	1
Compound of Example 28	2
Compound of Example 30	2
Compound of Example 32	1
Compound of Example 33	1.5
Compound of Example 35	1.5
Compound of Example 47	3.5

(2) Effect for preventing skin sunburn caused by UV rays irradiation (in vivo)

10

This test is an experimental model of quantitative evaluation of effect for preventing skin

sunburn, caused by UV rays irradiation, performed by the test compound. [Test was conducted by a modified method according to the procedures of J. Dermatol. Vol. 17, pp. 595-598, (1990).]

5 Hairs on the back of an albino guinea pig (Hartley strain, female, age of 7-8 weeks) were shaved by use of an electric hair clipper and an electric shaver. Next day, the guinea pig was fixed on a Bowman cage, a piece of shading tape (a plaster for patch test) having 4
10 circular holes of 1.5 cm in diameter was put on the shaved portion of the skin, and predetermined 2 sections of UV rays irradiation. One section (reference section) was coated with 10 μ l of a solvent (water or 50% ethanol-water solution). Another section (test section) was coated with
15 10 μ l of 3% test compound solution (aqueous or 50% ethanol-water solution). 30 Minutes after the coating, UV rays of 1.3-1.5 mW/cm² in strength was irradiated for 30 minutes by use of a fluorescent lamp of healthy light (TOSHIBA FL-20·SE) as a light source. 24 Hours after the irradiation, the
20 reference section (coated with the solvent only) and the test section (coated with test compound solution) were observed respectively, and the erythrochromia (Δ a value) on both reference section and test section were measured by use of a color difference meter (OFC-300A Type, mfd. by
25 NIHON DENSHOKU KOGYO CO., LTD). The inhibitory ratio of skin erythema (sunburn) performed by the test compound was calculated from the following formula.

Inhibitory ratio of skin

$$\text{erythema (sunburn) (\%)} = \{1 - [(C)/(D)]\} \times 100$$

[wherein (C): Δa Value of test section of skin coated with test compound solution,

5 (D): Δa Value of reference section of skin coated with the solvent only, and

Δa value: difference of skin erythema on the portion irradiated with UV rays].

The test results are shown in Table 16.

Table 16

Test compound	(C)	(D)	Inhibitory ratio of skin erythema (%)
Compound of			
Example 9	4.69 \pm 1.62**	7.61 \pm 0.99	38
Example 13	3.93 \pm 0.92**	6.71 \pm 1.21	42
Example 18	3.87 \pm 2.45**	7.50 \pm 1.24	51
Example 22	5.51 \pm 2.32**	8.52 \pm 1.33	37
Example 23	4.46 \pm 1.28**	8.27 \pm 1.46	46
Example 25	3.31 \pm 2.00**	8.87 \pm 1.66	64
Example 28	1.13 \pm 0.58**	5.03 \pm 1.03	78
Example 30	4.73 \pm 1.94**	7.91 \pm 1.31	40
Example 32	2.17 \pm 0.97**	6.07 \pm 0.97	64
Example 33	3.96 \pm 1.02**	7.73 \pm 1.11	49
Example 35	3.61 \pm 2.91 *	6.72 \pm 1.78	51
Example 47	0.88 \pm 0.29**	4.08 \pm 1.57	76

*: p<0.05,

**: p<0.01 (One way ANOVA followed by two-tailed

Dunnett's test)

(3) Effect for preventing skin pigmentation caused by
UV rays irradiation

This is an experimental model of quantitative evaluation of effect for preventing skin pigmentation 5 caused by UV rays irradiation performed by test compound.

[Test was conducted by a modified method according to procedures of J. Dermatol. Vol. 17, pp. 595-598, (1990).]

Hairs on the back of a colored guinea pig (A-1 strain, female, age of 8-10 weeks) were shaved and the body 10 of guinea pig was fixed on a Bowman cage, and predetermined 2 sections of UV rays irradiation. One section (reference section) was coated with 10 $\mu\text{l}/\text{cm}^2$ of a solvent (water or 50% ethanol-water solution). Another section (test section) was coated with 10 $\mu\text{l}/\text{cm}^2$ of 3% test compound 15 solution (aqueous or 50% ethanol-water solution). 30 Minutes after the coating, UV rays of intensity of 0.838 mV/cm^2 was irradiated for 50 minutes by use of a solar simulator (WXS-200s-20: mfd. by WAKOMU SEISAKUSHO) in which a xenone lamp of 150W (KXL-2003F: mfd. by WAKOMU 20 SEISAKUSHO) was installed as a light source. Intensity of the light (mV/cm^2) was measured by using a photometer (EPPLEY Thermopile 28571J3: mfd. by WAKOMU SEISAKUSHO). 14 Days after the irradiation, the brightness (ΔL value) of the skin of reference section and that of the test section 25 coated with test compound solution were measured by using a color difference meter (Digital color meter OFC-300A type: mfd. by NIHON DENSHOKU KOGYO). The inhibitory ratio of the skin pigmentation (%) performed by the test compound was

calculated from the following formula.

Inhibitory ratio of

$$\text{skin pigmentation (\%)} = \{1 - [(E)/(F)]\} \times 100$$

[wherein (E): ΔL value of brightness of the skin coated

5 with test compound solution (test section),

(F): ΔL value of brightness of the skin coated
the solvent (reference section), and

ΔL value: difference of brightness of the skin
between the portion without irradiated and the portion
10 irradiated with UV rays].

The results are shown in Table 17.

Table 17

Test compound	(E)	(F)	Inhibitory ratio of skin pigmentation (%)
Compound of			
Example 18	-3.53 ± 1.24*	-6.92 ± 1.61	49
Example 25	-5.02 ± 2.02	-8.04 ± 2.43	38
Example 28	-4.51 ± 1.87**	-7.90 ± 1.30	43
Example 30	-3.40 ± 1.18**	-6.77 ± 1.79	50
Example 32	-3.37 ± 2.36	-5.77 ± 2.36	42
Example 33	-2.61 ± 2.98*	-5.77 ± 2.36	55
Example 35	-4.44 ± 2.17	-6.84 ± 3.09	35
Example 47	-4.89 ± 1.24**	-7.90 ± 2.26	38

*: p<0.05, ** p<0.01 (One way ANOVA followed by two-tailed Dunnett's test)

(4) Skin sensitization test [Adjuvant and strip test:

J. Invest. Dermatol., Vol. 76, pp 498-501, (1981)]

This test was used as experimental model for evaluating the existence of toxicity of photosensitization 5 to the skin performed by the test compounds.

(i) Procedure for inducing photosensitization

Albino guinea pigs (Hertley strain, female, age of 5-6 weeks) were used. Hairs of the nuchal area of the guinea pig were shaved, and designated the test sample 10 coating section having 2 × 4 cm in size. At the four corners of the test sample coating section, 0.1 ml each of E-FCA (an emulsion consisting of the same volume each of Freund's complete adjuvant with sterilized distilled water) were intracutaneously injected. The coating section was 15 subjected to striping repeatedly by use of Cellophane tape until the section turned to slightly erythema, then 0.1 ml of test compound solution (aqueous or 50% ethanol-water solution) of 3% in concentration was open-coated on the section. 30 Minutes after the coating, UV rays of about 20 10J/cm² in dosage was irradiated by use of a fluorescent lamp of healthy light (TOSHIBA FL-20S-BLB) as a light source. The above-mentioned procedure was carried out once a day, and continuously conducted for 5 days, provided that E-FCA was administered only on the first day.

25 (ii) Procedure for introducing sensitization

3 Weeks after the beginning of induction period of photosensitization, the covering hairs on the back of guinea pig were shaved, and determined a circular section,

having 1.5 cm in diameter, for coating test samples, and 20 μ l of test compound solution (aqueous or 50% ethanol-water solution) of 3% in concentration was open-coated on the section. The test sample coated section was observed 24 hours and 48 hours, and examined existences of skin reaction (erythema and edema). In case of skin reaction was appeared, then it was determined as positive reaction in skin sensitization which was defined as a positive ratio (%) calculated from the following formula.

$$10 \quad \text{Positive ratio (\%)} = [(G)/(H)] \times 100$$

[wherein (G): Number of positive reactions in skin sensitization and

(H): Number of total animal tests].


The results are shown in Table 18.

Table 18

Test compound	Positive ratio (%)
Compound of	
Example 9	0
Example 13	0
Example 18	0
Example 22	0
Example 25	0
Example 28	0
Example 30	0
Example 32	0
Example 33	0
Example 35	0
Example 47	0

CLAIMS

1. A carbostyryl derivative or a salt thereof represented by the general formula (1),



(wherein R¹ is a hydrogen atom, a lower alkyl group or a lower alkenyl group; R² is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranyloxy group; R³ and R⁴ are the same or different from each other and are lower alkyl groups which may have hydroxyl groups as substituents; further R³ and R⁴ may form, together with the adjacent nitrogen atom, further with or without an additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered saturated heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond; provided that when R³ and R⁴ are lower alkyl groups at the same time, then R² should be neither a hydrogen atom, a lower alkyl group nor a lower alkoxy group).

2. The carbostyryl derivative or a salt thereof according to Claim 1, wherein R¹ is a hydrogen atom; R² is a hydrogen atom, a lower alkyl group or a lower alkoxy group.

3. The carbostyryl derivative or a salt thereof according to Claim 1, wherein R¹ is a hydrogen atom; R² is a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranloxy group.
4. The carbostyryl derivative or a salt thereof according to Claim 1, wherein R¹ is a lower alkyl group; R² is a hydrogen atom, a lower alkyl group or a lower alkoxy group.
5. The carbostyryl derivative or a salt thereof according to Claim 1, wherein R¹ is a lower alkyl group; R² is a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranloxy group.
6. The carbostyryl derivative or a salt thereof according to Claim 1, wherein R¹ is a lower alkenyl group; R² is a hydrogen atom, a lower alkyl group or a lower alkoxy group.
7. The carbostyryl derivative or a salt thereof according to Claim 1, wherein R¹ is a lower alkenyl group; R² is a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranloxy group.
8. The carbostyryl derivative or a salt thereof according to Claim 1, wherein the hydroxyl group is substituted at 5-position in the carbostyryl skeleton; R² is substituted at 6-position; and the group of the formula -CH₂NR³R⁴ is substituted at 8-position in the carbostyryl skeleton.
9. The carbostyryl derivative or a salt thereof according to Claim 1, wherein the carbon-carbon bond

between 3- and 4-positions in the carbostyryl skeleton is a single bond.

10. The carbostyryl derivative or a salt thereof according to Claim 1, wherein the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a double bond.

11. The carbostyryl derivative or a salt thereof according to any one of Claims 2 - 7, wherein R³ and R⁴ are lower alkyl groups which may have hydroxyl groups as substituents.

12. The carbostyryl derivative or a salt thereof according to any one of Claims 2 - 7, wherein R³ and R⁴ form, together with the adjacent nitrogen atom and further with or without an additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered saturated heterocyclic group.

13. A compound according to Claim 1, which is 3,4-dihydro-8-allyloxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone.

14. A compound according to Claim 1, which is 3,4-dihydro-8-allyloxy-5-hydroxy-6-morpholinomethyl-2(1H)-quinolinone.

15. A compound according to Claim 1, which is 3,4-dihydro-8-propoxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone.

16. A compound according to Claim 1, which is 3,4-dihydro-8-methyl-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone.

17. An agent for preventing and treating dermatopathy or dermatitis containing at least one selected from the group consisting of the carbostyryl derivative and salt thereof claimed in Claim 1.


18. The agent for preventing and treating dermatopathy or dermatitis according to Claim 17, wherein the carbostyryl derivative is 3,4-dihydro-8-allyloxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone, 3,4-dihydro-8-allyloxy-5-hydroxy-6-morpholinomethyl-2(1H)-quinolinone, 3,4-dihydro-8-propoxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone, 3,4-dihydro-8-methyl-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone or 3,4-dihydro-5-hydroxy-6-diethylaminomethyl-2(1H)-quinolinone.

19. An agent for inhibiting skin erythema and/or skin pigmentation containing at least one selected from the group consisting of the carbostyryl derivative and salt thereof as claimed in Claim 1.

20. The agent for inhibiting skin erythema or skin pigmentation according to Claim 19, wherein the carbostyryl derivative is 3,4-dihydro-8-allyloxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone, 3,4-dihydro-8-allyloxy-5-hydroxy-6-morpholinomethyl-2(1H)-quinolinone, 3,4-dihydro-8-propoxy-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone, 3,4-dihydro-8-methyl-5-hydroxy-6-(1-piperidinyl)methyl-2(1H)-quinolinone or 3,4-dihydro-5-hydroxy-6-diethylaminomethyl-2(1H)-quinolinone.


21. Use of compound for the production of a medicament for inhibiting skin erythema and/or skin

pigmentation containing at least one selected from the group consisting of the carbostyryl derivative and salt thereof represented by the general formula,




(wherein R¹ is a hydrogen atom, a lower alkyl group or a lower alkenyl group; R² is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranyloxy group; R³ and R⁴ are the same or different from each other and are lower alkyl groups which may have hydroxyl groups as substituents; further R³ and R⁴ may form, together with the adjacent nitrogen atom and further with or without an additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered saturated heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond).

22. Process for preparing a carbostyryl derivative represented by the general formula (1),



(wherein R¹ is a hydrogen atom, a lower alkyl group or a lower alkenyl group; R² is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkenyloxy group, a lower alkenyl group or a tetrahydropyranloxy group; R³ and R⁴ are the same or different from each other and are lower alkyl groups which may have hydroxyl groups as substituents; further R³ and R⁴ may form, together with the adjacent nitrogen atom and further with or without an additional nitrogen atom, sulfur atom or oxygen atom, a 5- or 6-membered saturated heterocyclic group which may have substituents selected from the group consisting of a lower alkyl group and a lower alkanoyl group; the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or double bond) by reacting a compound of the general formula (3),



(wherein R¹, R² and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined the above; and R⁵ is a hydrogen atom, a tetrahydropyranyl group or a lower alkanoyl group) with a compound of the general formula (4),




(wherein R³ and R⁴ are the same as defined the above), or a compound of the general formula (5),




(wherein R³ and R⁴ are the same as defined the above).

23. Process for preparing a carbostyryl derivatives represented by the general formula (1b),




(wherein R¹, R³, R⁴ and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined in Claim 22; and R^{2b} is a lower alkyl group or a lower alkyloxy group) by reducing a compound represented by the general formula (1a),




(wherein R¹, R³, R⁴ and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined in Claim 22; and R^{2a} is a lower alkenyl group or a lower alkenyloxy group).

24. Process for preparing a carbostyryl derivatives

represented by the general formula (1d),



(wherein R², R³, R⁴ and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined in Claim 22; and R^{1a} is a lower alkyl group or a lower alkenyl group) by reacting a compound of the general formula (1c),



(wherein R², R³, R⁴ and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton are the same as defined in Claim 22) with a compound of the general formula (8),



(wherein R^{1a} is the same as defined the above; and X is a halogen atom).

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/03657

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D215/26 A61K31/47 C07D215/22 C07D405/12

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 02508 A (OTSUKA PHARMACEUTICAL CO., LTD.) 1 February 1996 see claims 1,37,38 ---	1,17,19
A	EP 0 081 782 A (MERCK & CO., INC.) 22 June 1983 see page 3, line 3-9; claim 1 ---	1,17,19
A	EP 0 467 325 A (SYNTEX (U.S.A.) INC.) 22 January 1992 cited in the application * page 30-31: preparation 7, 8 * & JP 04 234386 A ---	1 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 October 1998

Date of mailing of the international search report

11/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 98/03657

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 638 571 A (KOWA CO., LTD.) 15 February 1995 cited in the application * page 102, reference example 21 * & WO 93 22317 A ----	1
A	CHEMICAL ABSTRACTS, vol. 119, no. 9, 30 August 1993 Columbus, Ohio, US; abstract no. 95292j, BLONDET, DOMINIQUE ET AL.: "Convenient synthesis of 6-methyl, 8-methyl and 6,8-dimethyl derivatives of 5-hydroxy-1,2,3,4-tetrahydro-2-quinolone." XP002081977 see abstract & ORG. PREP. PROCED. INT., vol. 25, no. 2, - 1993 pages 223-228, -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP 98/03657

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9602508	A	01-02-1996	AU 689281 B AU 2936195 A CA 2170520 A CN 1130377 A EP 0719258 A JP 8081442 A US 5786367 A	26-03-1998 16-02-1996 01-02-1996 04-09-1996 03-07-1996 26-03-1996 28-07-1998
EP 81782	A	22-06-1983	AT 16278 T CA 1219587 A DK 552682 A GR 77088 A JP 58109452 A US 4578390 A	15-11-1985 24-03-1987 15-06-1983 06-09-1984 29-06-1983 25-03-1986
EP 467325	A	22-01-1992	US 5082847 A AU 648090 B AU 8046191 A CA 2047307 A FI 913450 A IT 1252602 B JP 4234386 A PT 98350 A	21-01-1992 14-04-1994 23-01-1992 19-01-1992 19-01-1992 19-06-1995 24-08-1992 29-05-1992
EP 638571	A	15-02-1995	US 5576324 A CA 2134448 A WO 9322317 A	19-11-1996 02-11-1993 11-11-1993